Is peripheral blood or bone marrow a better source of stem cells for transplantation in cases of HLA-matched unrelated donors? A meta-analysis

Wu, Sha; Zhang, Cheng; Zhang, Xi; Xu, Yiyao; Deng, Tianxia

doi:10.1016/j.critrevonc.2015.04.009

Cited by 14 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In cancer treatments usually PBSC is the preferred choice as it has faster engraftment and offers more GVHD that in turn prevents relapse of the disease (36,37). On the other hand in non-malignant disease, BM graft is is preferred in patients.…”

Section: Different Types Of Hsct Graftsmentioning

confidence: 99%

Stem cell transplantation during cancer

Zhang

2016

Oncology Letters

View full text Add to dashboard Cite

Hematological malignancies account for approximately 9.5% of new cancers diagnosed annually. Lymphoma is the most frequent of all known categories of hematological malignancies. Worldwide, extensive research has focused on this type of cancer. However, new treatments are investigated in various clinical as well as pre-clinical studies. Hematopoietic stem cell transplantation (HSCT) is a recent and upcoming treatment strategy for patients with hematopoietic malignancies and inborn errors of metabolism or immune deficiencies. Recent studies have revealed that successful clinical outcome of this treatment strategy depends on multiple factors including the protocol applied, disease under treatment, health of the patient, source of the grafts, severity of complications such as graft versus host disease during grafting and associated infections. The scope of this review is to achieve greater understanding of various clinical effects of the disease and related mechanisms. The electronic database Pubmed was searched for pre-clinical as well as clinical controlled trials reporting efficacy of the HSCT against hematological malignancies.

show abstract

Section: Different Types Of Hsct Graftsmentioning

confidence: 99%

Stem cell transplantation during cancer

Zhang

2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Furthermore, after HSCT with MUD, a shorter time to absolute neutrophil count equal to 0.5 × 10 9 /L and a shorter time of platelet engraftment were reported in the PBSC compared to the BM group (153). Several other studies and a meta-analysis including eight different trials in MUD confirm these findings and showed a higher rate of engraftment in recipients of PBSC (146, 154, 155). …”

Section: Stem Cell Sourcesmentioning

confidence: 53%

“…Progression-free survival seems to be comparable between PBSC and BM recipients, and the risk of relapse appears to be lower in patients given PBSC (142, 151, 155). …”

Section: Stem Cell Sourcesmentioning

confidence: 96%

“…Moreover, high numbers of lymphocytes in the PBSC, namely, immunocompetent T-cells may enhance the GvL effect (145, 155). Unmodified PBSC grafts may contain one log more T-lymphocytes than unmodified BM grafts (156).…”

Section: Stem Cell Sourcesmentioning

confidence: 99%

“…Unmodified PBSC grafts may contain one log more T-lymphocytes than unmodified BM grafts (156). However, these high T-cell numbers could in parallel lead to a higher risk of GvHD (155, 156), which as a consequence may have a higher mortality. An increased incidence of chronic GvHD, but no difference in acute GvHD, was observed between PBSC and BM graft recipients in HLA-matched related settings by Campregher and colleagues (157).…”

Section: Stem Cell Sourcesmentioning

confidence: 99%

See 2 more Smart Citations

Milestones of Hematopoietic Stem Cell Transplantation – From First Human Studies to Current Developments

et al. 2016

View full text Add to dashboard Cite

Since the early beginnings, in the 1950s, hematopoietic stem cell transplantation (HSCT) has become an established curative treatment for an increasing number of patients with life-threatening hematological, oncological, hereditary, and immunological diseases. This has become possible due to worldwide efforts of preclinical and clinical research focusing on issues of transplant immunology, reduction of transplant-associated morbidity, and mortality and efficient malignant disease eradication. The latter has been accomplished by potent graft-versus-leukemia (GvL) effector cells contained in the stem cell graft. Exciting insights into the genetics of the human leukocyte antigen (HLA) system allowed improved donor selection, including HLA-identical related and unrelated donors. Besides bone marrow, other stem cell sources like granulocyte-colony stimulating-mobilized peripheral blood stem cells and cord blood stem cells have been established in clinical routine. Use of reduced-intensity or non-myeloablative conditioning regimens has been associated with a marked reduction of non-hematological toxicities and eventually, non-relapse mortality allowing older patients and individuals with comorbidities to undergo allogeneic HSCT and to benefit from GvL or antitumor effects. Whereas in the early years, malignant disease eradication by high-dose chemotherapy or radiotherapy was the ultimate goal; nowadays, allogeneic HSCT has been recognized as cellular immunotherapy relying prominently on immune mechanisms and to a lesser extent on non-specific direct cellular toxicity. This chapter will summarize the key milestones of HSCT and introduce current developments.

show abstract

Molecular Testing in the Assessment of Bone Marrow Transplant Engraftment

Booker¹

2017

Diagnostic Molecular Pathology

View full text Add to dashboard Cite

Is peripheral blood or bone marrow a better source of stem cells for transplantation in cases of HLA-matched unrelated donors? A meta-analysis

Cited by 14 publications

References 38 publications

Stem cell transplantation during cancer

Stem cell transplantation during cancer

Milestones of Hematopoietic Stem Cell Transplantation – From First Human Studies to Current Developments

Molecular Testing in the Assessment of Bone Marrow Transplant Engraftment

Contact Info

Product

Resources

About